AbbVie Inc. (ABBV)
Pre-market: 04:43AM EDT
| Previous close | 108.76 |
| Open | 108.67 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's range | 108.31 - 109.22 |
| 52-week range | 79.11 - 121.53 |
| Volume | 4,346,878 |
| Avg. volume | 7,141,750 |
| Market cap | 192.87B |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | 29.43 |
| EPS (TTM) | 3.71 |
| Earnings date | 29 Oct 2021 |
| Forward dividend & yield | 5.20 (4.76%) |
| Ex-dividend date | 14 Oct 2021 |
| 1y target est | 127.01 |
- Zacks
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.
- Motley Fool
3 Leading Healthcare Stocks to Buy in 2021 and Beyond
Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. ResMed is already an industry leader in sleep apnea therapies, an area that's expected to grow as our population ages. Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity that protects its long-term outlook.
